Rare diseases and not-so-rare bureaucratic delays

Policy announced last year gave hope to patients, but its implementation is yet awaited

Manjit Singh | November 23, 2018


#National Policy on Treatment of Rare Diseases   #healthcare   #Rare diseases   #health ministry  


Ashan was all of only 21 months when he lost his battle to a rare genetic disorder on November 18. During his last days at the Lok Nayak Jai Prakash Narayan hospital in the capital, his distraught family left no stone unturned, and appealed to various authorities for facilitating right treatment as promised under the National Policy on Treatment of Rare Diseases. To no avail.

The disease was rare; the case is not. Patients are losing lives as the government is yet to finalise the modalities of implementing the policy. When it was announced last year, it was widely welcomed, but it is now over 78 weeks and patients are still awaiting action. More than 20 children have lost their lives in this period, 10 alone in Tamil Nadu.

The policy has been entangled in bureaucratic hold-up between the centre and states. There has been no headway in the implementation process despite the favourable judicial intervention in many states to initiate the treatment. A corpus of Rs 100 crore announced in the policy remained unused, and lapsed with the end of the last financial year. 

Some efforts have indeed been made: for example, setting up the central technical committee (CTC), state technical committees (STCs) and the rare disease cell for the application process to initiate treatment. But did the move make the process of getting treatment easier for patients? No.

The tedious and lengthy application process is only adding up to the complications. At first, the family of the patient has to apply to the rare disease cell directly or through a designated state health hospital. The application is forwarded to the STC by the hospital, which further forwards it to CTC after necessary reviews. The funds are then supposed to be released to the designated hospital under the PIP (60:40 ratio), only once the CTC approves it. It is only after this tiring and cumbersome procedure that the treatment can be initiated. Sadly, not even a single patient has been enrolled or approved for treatment in over 17 months.

The rare disease cell of the health ministry has received 180-odd applications, but there has been no headway. The centre is taking its own time to formulate guidelines to give it a structure for processing the applications and providing treatment.

For those trying to cope with the prohibitively expensive nature of treatment, untimely diagnosis, lack of insurance coverage and lack of state or social security, this is an ordeal they do not deserve to go through.

Over the last one decade, patient groups, medical professionals, social stakeholders and also the judiciary have been striving to ensure treatment for rare disease patients. In fact, there have been umpteen representations to the centre to get the rare disease policy in place. The need of the hour is to recognise rare diseases as a health priority and not dismiss them as diseases that affect only a “selected few”, thereby, following the promises and recommendations made in the policy.

Until and unless concrete measures are taken and adopted to improve patient outcomes, the policy’s purpose will be defeated. There is a dire need to set in motion, an immediate call-to-action for the implementation of the National Policy for Treatment of Rare Diseases. It is time for the centre, states and the stakeholders to come together to combat rare diseases.

Singh is president of Lysosomal Storage Disorder Support Society

Comments

 

Other News

Four trends that will shape healthcare post-Covid

The Covid-19 pandemic has disrupted economies and healthcare systems across the world. Even in the countries like the US that have the highest spend on healthcare and public health emergency preparedness, the impact of coronavirus pandemic on health and livelihoods of people has been tremendous. There are

India to play leading role in global revival: Modi

India would play a leading role in the global revival, prime minister Narendra Modi said on Thursday, as he addressed the inaugural session of India Global week via video-conference. He said that this is closely linked with two factors. “First is - Indian talent and second is India`s

BMC spells out numbers to counter Fadnavis’ claims

The BrihanMumbai municipal corporation (BMC) has countered Maharashtra leader of opposition Devendra Fadanvis’s suspicions of fewer Covid-19 tests, as it outlined various measures it has adopted since the first test conducted on February 3, and how it has gradually brought down the number of cases in

Mumbai opts for “most liberal Covid-19 testing” in the world

As part of the four T strategy of trace-test-track-treat, Mumbai – the most affected city in India – has decided to make Covid-19 tests accessible to all. The municipal corporation of Greater Mumbai (MCGM) has come out with guidelines allowing all laboratories to conduct RT-PCR (

Exit the Dragon, Enter the Tiger

In a major development on July 6, the Chinese army started moving back its tents, vehicles as well as troops from locations where disengagement was agreed upon in eastern Ladakh’s Galwan Valley. This is a significant milestone in regional geopolitics with India having been successful in isolating the

Hiranandani Group launches ambitious data centre project

With the Covid-19 pandemic pushing more online activity and the capacity usage of data centres going up, India’s largest data centre (DC) building and the biggest tier-IV data centre, Yotta NM1,the  second largest in the world, has been launched in Mumbai. The launch event on Tue



Archives

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter